Prognostic values of long noncoding RNA PVT1 in various carcinomas: An updated systematic review and meta‐analysis

Abstract

Cancers have been a worldwide health problem with a high mortality rate, but ideal biomarkers are not available to effectively screen and diagnose patients. Currently, an increasing number of long noncoding RNAs have been reported to be abnormally expressed in human carcinomas and play a vital role in tumourigenesis. Plasmacytoma variant translocation 1 (PVT1) is upregulated in various carcinomas, and its overexpression is associated with poor survival in cancer patients. We conduct an updated meta-analysis to determine its potential in prognosis for tumours. In total, 14 studies comprising 2435 patients were enrolled according to Reporting Recommendations for Tumour Marker Prognostic Studies guidelines. High PVT1 expression indicated poor overall survival (hazard ratio [HR] = 1.98, 95% confidence interval [CI]: 1.62-2.42, P < 0.00001) and disease-free survival (HR = 1.63, 95% CI: 1.45-1.84, P < 0.00001). Additionally, increased PVT1 expression was positively associated with lymphatic node metastasis (odd ratio [OR] = 2.87, 95% CI: 1.66-4.96, P = 0.0002), distant metastasis (OR = 2.47, 95% CI: 1.74-3.50, P < 0.00001), advanced tumour-node-metastasis stages (OR = 2.59, 95% CI: 1.38-4.88, P = 0.003). New findings highlight that PVT1 acts as competing RNA to microRNAs to protect mRNAs from miRNAs repression. Therefore, we also discuss PVT1-related microRNAs and their interaction in tumourigenesis. In conclusion, PVT1 may be a potential biomarker of poor prognosis for patients with different cancer types.

Long non-coding RNA PVT1 interacts with MYC and its downstream molecules to synergistically promote tumorigenesis

“…PVT1 can promote the development of glioma cells through various mechanisms, resulting in a worse prognosis for patients with glioma and high PVT1 expression [18,161,162]. Multiple meta-analyses have also shown that PVT1 can be used as a new tumor biomarker and a predictor of poor prognosis in different cancers [163][164][165][166][167].…”

LncRNA SNHG22 Sponges miR-128-3p to Promote Progression of Colorectal Cancer through Upregulating E2F3

“…Dysregulation of lncRNAs in various types of the human tumor was associated with excellent or dismal survival, making them promising prognostic biomarkers. 19,20 For example, SNHG7 expression is enhanced in CRC tissues as compared with noncancerous tissues, and this high expression is related to aggressive pathological characteristics, such as TNM stage, lymphatic metastasis, and distant metastasis, as well as poor prognosis. 8,9 Upregulation of PVT1 was an indicator of dismal survival in several cancers, including CRC.…”

“…8,9 Upregulation of PVT1 was an indicator of dismal survival in several cancers, including CRC. 20 Some researchers have reported the upregulated expression of SNHG22 in EOC, PTC, and ccRCC, and whose expression indicated poor prognosis in the three types of human malignancies. [11][12][13] In this study, we rst explored the expression patterns of SNHG22 in ANT, CRA, and CRC tissues, and found that SNHG22 expression was gradually upregulated in ANTs, CRA, and TTs.…”

The prognostic value of lncRNA SNHG4 and its potential mechanism in liver cancer

“…There have been too many researches about long non-coding RNA and microRNA in the field of oncology. Also, some molecular has been recognized as novel biomarkers for prognosis, including XIST [2], PVT1 [3], and MALT1 [4]. Small nucleolar RNA host gene 4 (SNHG4), a novel non-coding RNA, has first reported in the research of directly irradiated and bystander cells and was found to be up-regulated in irradiated TK6 cells but were repressed in bystander cells [5].…”